OS Therapies (NYSE:OSTX) Given New $15.00 Price Target at Maxim Group

OS Therapies (NYSE:OSTX) had its price objective upped by Maxim Group from $8.00 to $15.00 in a research report released on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research note on Wednesday.

OS Therapies Stock Performance

Shares of NYSE OSTX opened at $4.12 on Thursday. The business has a 50 day moving average price of $3.32. OS Therapies has a 52-week low of $1.58 and a 52-week high of $7.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.